Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Dec:20:1533033820971610.
doi: 10.1177/1533033820971610.

PVT1 Expression Is a Predictor for Poor Survival of Prostate Cancer Patients

Jianhua Liu  1 , Yanqing Li  2 , Qiqi Zhang  3 , Chaoxiang Lv  3 , Mingwei Wang  4 , Yan Jiao  5 , Chunxi Wang  1
Affiliations

PVT1 Expression Is a Predictor for Poor Survival of Prostate Cancer Patients

Jianhua Liu et al. Technol Cancer Res Treat. 2021 Jan-Dec.

Abstract

Objective: Dysregulation of long noncoding RNA is associated with a variety of cancers and LncRNA has anticancer or carcinogenic activities. PVT1, as a long noncoding RNA, plays an important role in the development of cancer.

Methods: We use R to download and analyze the data in TCGA database. ROC curve is generated to evaluate the significance of PVT1 expression for the diagnosis of prostate cancer. Chi-square test is used to test correlation between PVT1 expression and clinical pathological features. Survival curve and univariate and multivariate cox regression analysis is performed to compare differences in the effect on the survival rate between PVT1 high expression and low expression.

Results: The expression of PTV1 in tumor tissues was significantly higher than that in normal tissues(P<2.2e-16). The difference of PTV1 expression was observed according to vital status (P = 0.0051) and Gleason score (P = 0.0012). The expression of PTV1 is significantly associated with T classification (P < 0.0001), N classification (P = 0.0499), PSA (P = 0.0001), Gleason Score (P < 0.0001), targeted molecular therapy (P = 0.0264) and vital status(P = 0.0036). The area under the ROC curve (AUC) was 0.860, which revealed PTV1 expression has excellent diagnostic value in prostate cancer. Patients with high PVT1 expression had a worse prognosis.

Conclusions: PVT1 expression may be a biomarker for the diagnosis and prognosis of prostate cancer.

Keywords: PVT1; biomarker; diagnosis; prognosis; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PVT1 expression pattern in prostate cancer. The difference in the expression of PVT1 between tumor tissue and normal tissue was compared, and the expression of PVT1 was compared according to different histological grade, stage, TNM classification, gender, age and vital status.
Figure 2.
Figure 2.
Diagnosis value of PVT1 expression in prostate cancer. The ROC curves of PVT1 expression in prostate cancer tissue and normal tissue of patients was generated.
Figure 3.
Figure 3.
The effect of PVT1 expression on OS in prostate cancer. Kaplan-Meier curves of PVT1 expression in all patients as well as subgroup analysis (N0, N1, M0, R0, R1_R2_RX and T2-T4).
Figure 4.
Figure 4.
The effect of PVT1 expression on RFS in prostate cancer. Kaplan-Meier curves of PVT1 expression in all patients as well as subgroup analysis (N0, N1, M0, R0, R1_R2_RX and T2-T4).
See this image and copyright information in PMC

References

    1. Jaworska D, Krol W, Szliszka E. Prostate cancer stem cells: research advances. Int J Mol Sci. 2015;16(11):27433–27449. doi:10.3390/ijms161126036 - PMC - PubMed
    1. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer a review. JAMA. 2017;317(24):2532–2542. doi:10.1001/jama.2017.7248 - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA-Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551 - PubMed
    1. Malouff TD, Stross WC, Seneviratne DS, et al. Current use of stereotactic body radiation therapy for lowand intermediate risk prostate cancer: a national cancer database analysis. Prostate Cancer Prostatic Dis. 2020;23(2):349–355. - PubMed
    1. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9):1508–1513. doi:10.1200/Jco.2009.22.2265 - PMC - PubMed

MeSH terms